Fine Vine: Old Dog,...
Health Care: Drugs
Opexa Therapeutics Inc. (OPXA: NASDAQ)
$1.67 -0.07 | -4.02%
05/17/13 - 03:59 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 592.00K | 7.11M | 3.81M | 8.18M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.08M | 124.77K | 85.52K | 187.31K |
| Total Current Assets | 1.67M | 7.23M | 3.90M | 8.37M |
| Property, Plant & Equipment, Gross | 2.76M | 2.22M | 1.93M | 1.98M |
| Accumulated Depreciation & Depletion | 1.49M | 1.19M | 1.11M | 1.03M |
| Property, Plant & Equipment, Net | 1.27M | 1.03M | 815.96K | 949.91K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.21M | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 2.48M | 1.03M | 815.96K | 949.91K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 4.15M | 8.26M | 4.71M | 9.32M |
| Accounts Payable | 412.10K | 491.32K | 373.84K | 625.60K |
| Short Term Debt | 0.00 | 0.00 | 35.61K | 67.31K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 885.98K | 1.07M | 745.30K | 833.97K |
| Long Term Debt | 376.76K | 0.00 | 0.00 | 1.02M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 86.80K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 376.76K | 0.00 | 0.00 | 1.11M |
| Total Liabilities | 1.26M | 1.07M | 745.30K | 1.94M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 2.88M | 7.20M | 3.97M | 7.38M |
| Common Par | 62.49K | 230.48K | 184.67K | 154.76K |
| Additional Paid In Capital | 112.43M | 107.65M | 98.50M | 96.46M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -109.61M | -100.68M | -94.71M | -89.24M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 3.26M | 7.20M | 3.97M | 8.40M |
| Total Equity | 2.88M | 7.20M | 3.97M | 7.38M |
| Total Liabilities & Stock Equity | 4.15M | 8.26M | 4.71M | 9.32M |
| Total Common Shares Outstanding | 6.25M | 5.76M | 4.62M | 3.87M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 5.79M | 5.63M | 4.27M | 3.14M |
| Diluted Weighted Shares Outstanding | 5.79M | 5.63M | 4.27M | 3.14M |
| Number of Employees | 26 | 19 | 11 | 10 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with OPXA
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Userneed cash
- UserYaYa
- UserHealthCare Dares
- UserBENITRANS CX
- ContributorStockerblog.com Stem Cell S...
- UserSAGJ
Latest OPXA Headlines from TheStreet
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Rebound Sharply; S&P 500, Nasdaq Rise Over 1% 02.05.13 | 04:02 pm
- Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug 02.05.13 | 10:02 am
- 5 Stocks Poised for Breakouts 10.12.12 | 01:10 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Biotech Stock Mailbag: Best Stocks to Watch in '11 01.07.11 | 07:01 am
- Opexa Therapeutics Reports Third Quarter 2010 Financial Results 11.09.10 | 08:11 am
- Otix Global, Entropic: Volume Movers 09.13.10 | 02:09 pm
- Biotech Stock Mailbag: Vertex Pharma 04.09.10 | 07:04 am
- Versar, Opexa Therapeutics: Midday Volume Plays 03.30.10 | 11:03 am
Press Releases for OPXA
- Opexa Therapeutics To Present At The 6th Annual European Life Science CEO Forum - Business Wire 03.04.13 | 08:03 am
- Opexa Therapeutics, Inc. Announces Pricing Of Common Stock And Warrant Offering - Business Wire 02.07.13 | 09:02 am
- Opexa Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.07.13 | 08:02 am
- Merck Serono And Opexa Therapeutics Enter Into Option And License Agreement For Development Of Tcelna™ (imilecleucel-T) For Treatment Of Multiple Sclerosis - Business Wire 02.05.13 | 07:02 am
- Opexa Therapeutics Closes Private Note Offering - Business Wire 01.23.13 | 05:01 pm
- Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement - Business Wire 01.15.13 | 08:01 am
- Opexa Therapeutics Announces Reverse Stock Split - Business Wire 12.14.12 | 04:12 pm
- Opexa Therapeutics Reports Third Quarter 2012 Financial Results And Provides Corporate Update - Business Wire 11.14.12 | 08:11 am
- Opexa Receives Clinical Trial Approval From Health Canada For Novel T-Cell Therapy - Business Wire 11.13.12 | 08:11 am
- Opexa Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.12.12 | 03:11 pm
Partner Headlines for OPXA
- Benzinga's Microcap Movers for Friday July 13, 2012 - Benzinga 07.14.12 | 04:07 pm
- A Busy Week for Multiple Sclerosis News - Seeking Alpha 09.26.10 | 08:09 am
